Our study indicated that the incidence of FN in patients with DLBCL who received the first cycle R-CHOP-21 without primary G-CSF prophylaxis was 20.4%, which means that R-CHOP-21 itself is a high-risk regimen for FN. This evidence concerns the gene CSF3 and diffuse large B-cell lymphoma.